Target-  | 
MechanismHepatitis C virus replication inhibitors   | 
 | 
 | 
 | 
Inactive Indication-  | 
Drug Highest PhasePhase 1  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Target-  | 
Mechanism-  | 
Active Org.-  | 
 | 
Active Indication-  | 
Inactive Indication-  | 
Drug Highest PhasePending  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
 | 
Mechanismneuraminidase inhibitors   | 
Active Org.-  | 
 | 
Active Indication-  | 
 | 
Drug Highest PhasePending  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza
This study tests the safety and effectiveness of a flu vaccine in school children.
School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu vaccine can help prevent the spread of the flu to other members of the community.
 / Unknown statusNot Applicable An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19
The observational study will be carried out in two stages. At the first stage, the efficacy and safety of Aprotinin intravenous infusion as add-on therapy to the standard of care will be studied. At the second stage, two groups will be included: the first group will be the inhaled Aprotinin add-on therapy, the second group will be intravenous Aprotinin in combination with Favipiravir.
100 Clinical Results associated with Aviron LLC
0  Patents (Medical) associated with Aviron LLC
100 Deals associated with Aviron LLC
100 Translational Medicine associated with Aviron LLC